Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group.
Anderson
G
G
Newport Chest Clinic, U.K.
Clavel
M
M
Smyth
J
J
Giaccone
G
G
Gracia
M
M
Planting
A S
AS
Dalesio
O
O
Kirkpatrick
A
A
McVie
G
G
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D004611:Ellipticines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007364:Intercalating Agents / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; D007364:Intercalating Agents; C027767:elliptinium